China's Clover Biopharmaceuticals jumps as co set to launch COVID vaccine in Q1

Clover Biopharmaceuticals

16/01/2023 03:59

** Shares of China's vaccine developer Clover
Biopharmaceuticals Ltd  2197.HK  jump as much as 11.7% to
HK$3.06, their highest since Dec 23, 2022
    ** Stock on course for a second consecutive session of gains
    ** Stock mark biggest intraday pct gain since Dec 20 
    ** Clover expects the commercial launch for its COVID-19
vaccine SCB-2019 in China to begin in Q1 2023  urn:newsml:reuters.com:*:nFWN33Z03Q
    ** Co says it anticipates a significant and sustained
long-term annual booster market opportunity in China for its
COVID-19 vaccine  
    ** The Hang Seng Commerce & Industry Index  .HSNC  gains
0.4% and the healthcare index  .HSCIH  surges 3.5%
    ** The Hang Seng Composite Index  .HSCI  rises 0.7% and the
Hang Seng Index  .HSI  climbs 0.5%
 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))